These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24946464)

  • 1. [The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].
    Tybura P; Mak M; Samochowiec A; Pełka-Wysiecka J; Grzywacz A; Grochans E; Zaremba-Pechmann L; Samochowiec J
    Psychiatr Pol; 2013; 47(4):567-78. PubMed ID: 24946464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.
    Tybura P; Samochowiec A; Beszlej A; Grzywacz A; Mak M; Frydecka D; Bieńkowski P; Mierzejewski P; Potemkowski A; Samochowiec J
    Pharmacol Rep; 2012; 64(3):528-35. PubMed ID: 22814006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
    Tybura P; Trześniowska-Drukała B; Bienkowski P; Beszlej A; Frydecka D; Mierzejewski P; Samochowiec A; Grzywacz A; Samochowiec J
    Psychiatry Res; 2014 Oct; 219(2):261-7. PubMed ID: 24930580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.
    van Veelen NM; Grootens KP; Peuskens J; Sabbe BG; Salden ME; Verkes RJ; Kahn RS; Sitskoorn MM
    Schizophr Res; 2010 Jul; 120(1-3):191-8. PubMed ID: 20493663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Harvey PD; Siu CO; Romano S
    Psychopharmacology (Berl); 2004 Mar; 172(3):324-32. PubMed ID: 14615877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone and cognition: the evolving story.
    Harvey PD
    J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perazine and carbamazepine in comparison to olanzapine in schizophrenia.
    Ohlmeier MD; Jahn K; Wilhelm-Gossling C; Godecke-Koch T; Hoffmann J; Seifert J; Emrich HM; Schneider U
    Neuropsychobiology; 2007; 55(2):81-8. PubMed ID: 17570951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in prosocial functioning after a switch to ziprasidone treatment.
    Loebel A; Siu C; Romano S
    CNS Spectr; 2004 May; 9(5):357-64. PubMed ID: 15115948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia.
    Harvey PD; Meltzer H; Simpson GM; Potkin SG; Loebel A; Siu C; Romano SJ
    Schizophr Res; 2004 Feb; 66(2-3):101-13. PubMed ID: 15061242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.
    Suzuki H; Gen K; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):161-8. PubMed ID: 21047544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
    Cuesta MJ; Peralta V; Zarzuela A
    Schizophr Res; 2001 Mar; 48(1):17-28. PubMed ID: 11278151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.
    Rossi A; Vita A; Tiradritti P; Romeo F
    Int Clin Psychopharmacol; 2008 Jul; 23(4):216-22. PubMed ID: 18545060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.